iOrganBio has appointed Karol Jarzabek as its Chief Operating Officer, bringing extensive private equity and operational expertise to help scale the company’s mission in intelligent cell manufacturing. The appointment comes as iOrganBio advances its AI-powered CellForge™ platform, designed to enable reliable, reproducible, and scalable production of human cells and organoids for research, drug development, and cell therapies. Daniel Delubac, co-founder and CEO of iOrganBio, highlighted Jarzabek’s track record in transforming life science organizations. “Karol brings extensive experience designing operational structures and aligning teams across life science businesses, with a proven track record of translating strategy into measurable results,” Delubac said. He noted Jarzabek’s prior success in growing a pharmaceutical company from $30 million to over $500 million in net revenue and turning a struggling brands division into a profitable unit generating $800 million in gross revenue. As COO, Jarzabek will lead iOrganBio’s operations, manufacturing, and supply chain functions, ensuring seamless execution as the company scales its CellForge platform. His role will also include driving regulatory alignment and cross-functional coordination across engineering, data science, and production teams. Jarzabek brings a unique blend of strategic and operational leadership, with deep experience in biopharmaceuticals and AI-enabled systems. Most recently, he served as Vice President of Portfolio Operations at QHP Capital, where he oversaw value creation across 13 life science and pharmaceutical services companies. Prior to that, he held senior roles at Azurity Pharmaceuticals, including Vice President of Strategic Finance and President of Established Brands, where he led M&A integration, portfolio management, and operational transformation. “I was impressed by how intentionally iOrganBio designed its platform from the start,” Jarzabek said. “The integration of science, data infrastructure, and engineering rigor creates a foundation that can truly scale. This approach has the potential to fundamentally change how therapies are developed, and I’m excited to help build the operational backbone that will support this vision.” iOrganBio’s CellForge platform leverages AI and automation to guide cell development in real time, using digital blueprints from its CellAtlas™—a comprehensive reference built from single-cell and multi-omics data. This closed-loop system ensures high accuracy, consistency, and quality, enabling faster and more reliable progress in disease modeling, regenerative medicine, and drug discovery. Headquartered at BioLabs in Chapel Hill, North Carolina, iOrganBio is redefining how human cells are produced, with a focus on meeting regulatory standards and advancing next-generation therapies. For more information, visit iOrgan.Bio or follow the company on LinkedIn.